鸟氨酸-天门冬氨酸联合乳果糖治疗肝性脑病疗效观察

目的探讨鸟氨酸-天门冬氨酸(雅博司)联合乳果糖治疗肝性脑病的疗效.方法选择56例肝性脑病患者,在综合性治疗的基础上,给鸟氨酸-天门冬氨酸20g/d静脉滴注;乳果糖20ml口服或鼻饲,每日三次.另选36例患者作为对照组,给一般综合性治疗,同时给乙酰谷酰胺1.0g/d静脉滴注,分别治疗20天.结果治疗组病死率明显下降,与对照组相比,有显著性差异(x2=4.02,P＜0.05),在降低血氨及促进脑电图改善方面,两组也存在显著性差异.结论雅博司联合乳果糖治疗慢性重型肝炎合并的肝性脑病,疗效显著,值得研究和应用.     

病毒性肝炎60例临床与病理分析

对６０例病毒性肝炎患者进行肝穿刺活检，结果发现，临床与病理诊断的符合率为４６．６％，其中，急性肝炎的诊断符合率最低（２３．８％），慢性迁延型肝炎（慢迁肝）为４４．８％；ＨＢｓＡｇ阳性首次发病的患者中，急性乙型肝炎仅为１１．２％（２／１８）；临床诊断的慢性活动型肝炎（慢活肝）仅为病理检出的２５．７％（９／３５）；肝炎患者中脾肿大，凝血酶元时间延长、Ａ／Ｇ值＜１．２、抗ＨＢｃＩｇＭ阳性可作为慢活肝与慢迁肝鉴别的重要指标。这些对提高病毒性肝炎临床分型诊断的准确率及指导临床治疗有意义。     

血清前－S_2蛋白检测的临床意义

采用ＥＬＩＳＡ法检测１０４例各类型乙型肝炎（乙肝）患者的血清前－Ｓ２抗原（Ｐｒｅ－Ｓ２Ａｇ）及其抗体（Ｐｒｅ－Ｓ２Ａｂ），结果表明，Ｐｒｅ－Ｓ２Ａｇ的出现与ＨＢｓＡｇ、ＨＢｅＡｇ、ＨＢｃＡｂ呈显著相关性（Ｐ值均＜０．００５），主要见于乙肝急性期及慢性乙肝患者，说明病毒复制活跃、传染性强。而Ｐｒｅ－Ｓ２Ａｂ阳性仅见于急性乙肝恢复期。     

慢性乙型肝炎的中医药生态治疗优势

现代医学的生物、心理与社会医学模式特点之一是对以身心疾病为主的现代疾病的预防和治疗 ,更加注重人体的整体性、强调药物作用的多靶点性 ,即整体调节作用。运用中医学的整体观与辩证论治治疗慢性疾病。如肝病的生态治疗就是发挥绿色天然中药复方的多重综合、双向调节功能 ,调动人体的防御机能 ,强调药物作用的多靶点性及整体调节作用以清除病毒、调节免疫、增强抵抗力、恢复肝功能、防止肝炎的慢性纤维化     

Prevalence of hepatitis C virus antibody in an area endemic for hepatitis B virus and human T cell leukaemia virus

To clarify the prevalence of concurrent infection with hepatitis C virus (HCV), hepatitis B virus (HBV) and human T cell leukaemia virus (HTLV), we measured HCV antibody in the population of a district endemic for HBV and HTLV infection. Blood samples were collected in June 1990 from 579 inhabitants of four islands of Uwa Bay in the southwest of Ehime Prefecture in Japan. Anti-HCV antibody against C100-3 protein was detected using an enzyme-linked immunosorbent assay kit (Ortho Diagnostics). Thirteen of the 579 inhabitants (2.2%) were positive for anti-HCV, and this prevalence rate was not significantly different from the frequency of anti-HCV in Tokyo blood donors. A total of 11% (64 of 579) of the subjects were positive for HBsAg and 3.3% (19 of 579) were positive for anti-HTLV. These frequencies of HBsAg and anti-HTLV positivity were distinctly higher than the respective means of Japanese. All anti-HCV positive individuals were negative for HBsAg and anti-HTLV, while 54% (7 of 13) had increased alanine aminotransferase levels. These data suggest that the prevalence of HCV infection is not high even in an area endemic for HBV and HTLV infection.     

Evaluation of the Crithidia assay to distinguish between auto-immune chronic active hepatitis and systemic lupus erythematosus

The aim of this study was to determine if the Crithidia luciliae assay for auto-antibodies to double-stranded DNA, often positive in systemic lupus erythematosus, is always negative in auto-immune chronic active hepatitis (CAH) as has recently been suggested. Twenty-five patients were identified as having auto-immune CAH. Mean duration of follow-up was 10.5 years. Antinuclear antibodies were detected in 92%, smooth muscle antibodies in 76% and antimitochondrial antibodies in 16%. Antibodies to double-stranded DNA were detected by the Crithidia assay in four patients (16%). Two of these patients had positive tests on only one occasion and no features of systemic lupus erythematosus. In the other two the assay was persistently positive. During follow-up both developed arthritis and serositis but the liver lesion remained the dominant clinical feature. It was concluded that there is significant serological overlap between auto-immune CAH and systemic lupus erythematosus making the Crithidia assay unreliable in distinguishing between them.     

Interactions Between Cytomegalovirus, Human Herpesvirus-6, and the Recurrence of Hepatitis C After Liver Transplantation

Recurrence of hepatitis C (HCV) following liver transplantation is common. Herpesvirus reactivation following transplant may have an immunomodulatory effect resulting in increased HCV replication. We studied whether cytomegalovirus (CMV) and human herpesvirus-6 (HHV-6) may be associated with HCV recurrence and viral load after transplant. We prospectively followed 66 HCV liver-transplant recipients with serial viral load testing for CMV and HHV-6. Infection and viral load were correlated with the development of biopsy-proven HCV recurrence and HCV viral loads. Histologic recurrence of HCV occurred in 41/66 (62.1%) patients. In the primary analysis, CMV infection and disease, and HHV-6 infection were not associated with HCV recurrence. Peak CMV and HHV-6 viral loads were not significantly different in patients with and without recurrence. No correlation was observed between HCV viral loads at 1 and 3 months post-transplant and peak HHV-6 or CMV viral loads. In a subgroup analysis, HHV-6 infection was associated with the development of more severe recurrence (hepatitis and/or fibrosis score > or = 2) (p = 0.01). Also, fibrosis scores at last follow up were higher in patients with CMV disease (1.67 vs. 0.56; p = 0.016) and in patients with HHV-6 infection (1.18 vs. 0.55; p = 0.031). In conclusion, HHV-6 and CMV infection and viral load were not associated with increased overall rates of HCV recurrence or HCV viral load after liver transplantation but may be associated with more severe forms of recurrence.     

7810例乙肝表面抗原和谷丙转氨酶结果分析

乙型病毒性肝炎 Virus B hepatitis(VBH) ,是目前严重危害人类健康水平的重要疾病之一。乙型肝炎病毒在人群中流行面广 ,传播途径多等特点。而我国地广人多 ,是乙肝发病率较高的国家。故对乙型肝炎的易感人群的保护尤其重要。因此 ,我们对山东省德州市 7810人进行了谷丙转氨酶     

肝康胶囊对慢性肝炎的疗效观察

目的 观察肝康胶囊对慢性乙型肝炎的疗效。方法 36例慢性中度肝炎随机分为二组,治疗组给予肝康胶囊口服,每日3次,每次6～8粒,连服1个月为一疗程,根据病情可连服2～3个疗程;对照组给服大黄蛰虫丸,疗程同前。在服药期间定期查肝功能、γ球蛋白、血清透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(C-Ⅳ)和层粘蛋白(LN)。结果 治疗组丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)和总胆红素(TB)下降速度明显快于对照组;自觉症状的改善情况也好于对照组;3个疗程后治疗组各项肝纤维化指标以及γ球蛋白均较治疗前显著下降(P<0.01),而对照组变化不甚明显。结论 肝康胶囊对慢性肝炎有良好的抗纤维化和改善肝功能作用。